ResMed Inc (STU:RME)
€ 238 -0.2 (-0.08%) Market Cap: 33.56 Bil Enterprise Value: 33.96 Bil PE Ratio: 32.69 PB Ratio: 6.97 GF Score: 98/100

ResMed Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 04, 2024 / 02:00PM GMT
Release Date Price: €217 (-0.50%)
Sean Laaman
Morgan Stanley & Co. LLC - Analyst

Good morning, everyone, and welcome to Morgan Stanley's Global Healthcare Conference. I'm Sean Laaman, I was the Australian healthcare analyst. I'm now a member of the US biotech team, having moved over about 10 days ago. But anyway, it's not about me. It's about ResMed, and I'm pleased to introduce Mick Farrell, Chairman and CEO. So thank you for your time today, Mick, greatly appreciate it again.

Mick Farrell
Resmed Inc - Chairman of the Board & CEO

Yes. Happy to be here, Sean. And thank you for doing double duty, new job and your old one after 22 years of covering us.

Questions & Answers

Sean Laaman;Mick
Morgan Stanley & Co. LLC - Analyst

Always. That's right. You have a lot of knowledge in there. But yes, I guess just to kick things off, Mick, just thinking about the long term, how would you describe patient volume diagnosis rates around the globe and various penetration rates and what does the runway for growth look like?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot